Zeevruchten: Microplastics op je bord?

Onze samenleving lijdt aan een ‘plastic passion’. Plastic is werkelijk overal. Tot in zeevruchten tref je minuscule stukjes plastic, zogenaamde microplastics, aan. Microplastics is de naam voor stukjes plastic kleiner dan 5mm. Soms zijn ze zo gemaakt, denk maar aan de plastic pellets als grondstof gebruikt in de plasticindustrie of als schuurparels in verzorgingscrubs. Maar microplastics kunnen ook ontstaan door het uiteenvallen van grote stukken plastic afval of bij het wassen van synthetische kledij. Je vindt deze plastic vezeltjes en stukjes in onder andere mosselen en Noordzeegarnalen. De aanwezigheid van microplastics in ons voedsel haalt vaak het nieuws en zorgt voor ongerustheid bij de liefhebbers van al het lekkers uit zee. Maar moeten we ons ook echt zorgen maken

Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma:A Systematic Review

BACKGROUND: Understanding molecular pathogenesis of head and neck squamous cell carcinomas (HNSCC) has considerably improved in the last decades. As a result, novel therapeutic strategies have evolved, amongst which are epidermal growth factor receptor (EGFR)-targeted therapies. With the exception of cetuximab, targeted therapies for HNSCC have not yet been introduced into clinical practice. One important aspect of new treatment regimes in clinical practice is presence of robust biomarkers predictive for therapy response.METHODS: We performed a systematic search in PubMed, Embase and the Cochrane library. Articles were included if they investigated a biomarker for targeted therapy in the EGFR-PI3K-AKT-mTOR-pathway.RESULTS: Of 83 included articles, 52 were preclinical and 33 were clinical studies (two studies contained both a preclinical and a clinical part). We classified EGFR pathway inhibitor types and investigated the type of biomarker (biomarker on epigenetic, DNA, mRNA or protein level).CONCLUSION: Several EGFR-PI3K-AKT-mTOR-pathway inhibitor biomarkers have been researched for HNSCC but few of the investigated biomarkers have been adequately confirmed in clinical trials. A more systematic approach is needed to discover proper biomarkers as stratifying patients is essential to prevent unnecessary costs and side effects.</p